SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. completed its de-SPAC transaction with Big Cypress Acquisition Corp (Nasdaq: BCYP), a blank-check company sponsored by Big Cypress Holdings LLC that conducted its initial public offering in 2021. The combination brought SAB Biotherapeutics, a clinical-stage biopharmaceutical company developing fully human polyclonal antibody therapies using genetically engineered cattle, into the public markets under the healthcare and biotechnology sector. The 10-Q filed on November 22, 2021 reflects the company's first quarterly reporting period following the close of the business combination in October 2021, with the combined entity subsequently trading under the ticker SABS on Nasdaq. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on this and hundreds of other transactions.